Study of ivonescimab and chemotherapy for advanced appendix cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of a new drug, ivonescimab, with chemotherapy given directly into the belly for people whose appendix cancer has spread and cannot be removed with surgery. The goal is to see if this treatment can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with appendix cancer that has spread and cannot be surgically removed.
- You must have had no more than two previous cancer treatments.
- You must be well enough to carry out daily activities (ECOG score 0-2).
- You must have adequate nutrition and normal bowel function.
- You must have acceptable blood counts, kidney, and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ivonescimab for people with advanced adrenal gland tumors (adrenocortical carcinoma or pheochromocytoma/paraganglioma) that cannot be removed with surgery. The goal is to see if the drug can reduce or stop the growth of the tumors.
This trial tests a new drug called Ivonescimab (AK112) combined with two chemotherapy drugs (Abraxane and cisplatin) given before surgery for esophageal cancer. The goal is to see if this combination can shrink tumors and improve surgery outcomes for patients with locally advanced disease.
This trial tests a chemotherapy drug (paclitaxel) given directly into the belly for people whose appendix cancer has spread inside the belly and cannot be surgically removed. The goal is to see if this approach is safe and helps shrink tumors.
This trial tests a combination of two drugs – ivonescimab (a type of immunotherapy) and TAS-102 (a chemotherapy) – for people with advanced colorectal cancer that has not responded to at least two prior chemotherapies. The goal is to see if this new combo can shrink tumors or slow cancer growth.
This trial tests a new immunotherapy drug called ivonescimab given together with standard chemotherapy for advanced stomach cancer. It may help your immune system fight the cancer more effectively.
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
Hear when a new Ivonescimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.